EG VEGF Mouse
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.
Description
Product Specs
Product Science Overview
EG-VEGF was first identified in 2001 as a tissue-specific angiogenic factor predominantly expressed in steroidogenic organs such as the adrenal gland, testes, ovary, and placenta . Unlike the more widely known Vascular Endothelial Growth Factor (VEGF), which is expressed in various tissues, EG-VEGF’s expression is largely restricted to endocrine glands .
The mouse ortholog of EG-VEGF shares a high degree of similarity with its human counterpart, with the cDNA and predicted amino acid sequences being 86% and 88% identical, respectively . Interestingly, the expression pattern of mouse EG-VEGF differs from that of the human protein. In mice, EG-VEGF is predominantly expressed in the liver and kidney, rather than in steroidogenic glands . This suggests that EG-VEGF may have different roles in regulating organ-specific angiogenesis in mice compared to humans.
EG-VEGF functions by binding to its receptors on the surface of endothelial cells, triggering a cascade of signaling events that lead to endothelial cell proliferation, migration, and the formation of fenestrations (small pores) in the capillary walls . This is particularly important in endocrine glands, where efficient blood supply is essential for hormone transport.
The expression of EG-VEGF is induced by hypoxia (low oxygen levels), which is a common condition in rapidly growing tissues and tumors . This hypoxia-induced expression ensures that growing tissues receive an adequate blood supply to meet their metabolic needs.
Research on EG-VEGF has provided valuable insights into the mechanisms of angiogenesis and its regulation in endocrine tissues. Studies have shown that EG-VEGF plays a critical role in the development and function of endocrine organs, as well as in pathological conditions such as tumors .
Recombinant forms of mouse EG-VEGF are used in various research applications to study its effects on endothelial cells and to explore potential therapeutic applications. For example, understanding how EG-VEGF promotes angiogenesis could lead to new treatments for diseases characterized by poor blood supply, such as ischemic heart disease and peripheral artery disease.
